(Q41718745)

8 October 2017

1 reference

title

Current issues in onychomycosis (English)

1 reference

8 October 2017

E F Trépanier

1

1 reference

8 October 2017

G W Amsden

series ordinal

2

1 reference

8 October 2017

language of work or name

English

0 references

publication date

1 February 1998

1 reference

Annals of Pharmacotherapy

8 October 2017

published in

1 reference

8 October 2017

volume

32

1 reference

8 October 2017

issue

2

1 reference

8 October 2017

page(s)

204-214

1 reference

Onychomycosis is more than a cosmetic problem

8 October 2017

cites work

1 reference

Quality of life of persons with onychomycosis.

21 January 2018

1 reference

Superficial fungal infections of the skin. Diagnosis and current treatment recommendations

21 January 2018

1 reference

Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology)

21 January 2018

1 reference

Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy.

21 January 2018

1 reference

Evolving role of nondermatophytes in onychomycosis

21 January 2018

1 reference

Terbinafine in onychomycosis with involvement by non-dermatophytic fungi

21 January 2018

1 reference

The role of yeasts in onychomycosis

21 January 2018

1 reference

New therapies for onychomycosis

21 January 2018

1 reference

Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions

21 January 2018

1 reference

Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases

21 January 2018

1 reference

Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses

21 January 2018

1 reference

Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections

21 January 2018

1 reference

Oral azole drugs as systemic antifungal therapy

21 January 2018

1 reference

Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients

21 January 2018

1 reference

Pharmacokinetics of terbinafine in the nail

21 January 2018

1 reference

Itraconazole penetrates the nail via the nail matrix and the nail bed--an investigation in onychomycosis

21 January 2018

1 reference

Open randomized comparison of itraconazole versus terbinafine in onychomycosis

21 January 2018

1 reference

Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group

21 January 2018

1 reference

Short term treatment of dermatophyte onychomycosis with terbinafine

21 January 2018

1 reference

A randomized treatment duration-finding study of terbinafine in onychomycosis

21 January 2018

1 reference

Terbinafine in onychomycosis of the toenail: A novel treatment protocol

21 January 2018

1 reference

Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy

21 January 2018

1 reference

A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail

21 January 2018

1 reference

A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail

21 January 2018

1 reference

Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole

21 January 2018

1 reference

Onychomycosis: successful treatment with once-weekly fluconazole

21 January 2018

1 reference

Fluconazole in the treatment of severe onychomycosis

21 January 2018

1 reference

Itraconazole in onychomycosis: intermittent dose schedule.

21 January 2018

1 reference

Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses

21 January 2018

1 reference

Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers

21 January 2018

1 reference

Cyclosporine and itraconazole interaction in heart and lung transplant recipients

21 January 2018

1 reference

Itraconazole and cyclosporin nephrotoxicity

21 January 2018

1 reference

Potentiation of action of warfarin by itraconazole

21 January 2018

1 reference

Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations

21 January 2018

1 reference

Increased gastric pH and the bioavailability of fluconazole and ketoconazole.

21 January 2018

1 reference

Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers

21 January 2018

1 reference

Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man

21 January 2018

1 reference

Induction of fluconazole metabolism by rifampin: in vivo study in humans.

21 January 2018

1 reference

Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model

21 January 2018

1 reference

Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections

21 January 2018

1 reference

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

21 January 2018

1 reference

Mycology of nail disorders

21 January 2018

1 reference

Onychomycosis and AIDS. Clinical and laboratory findings in 62 patients

21 January 2018

1 reference

Non-dermatophytes in onychomycosis of the toenails

21 January 2018

1 reference

Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study

21 January 2018

1 reference

Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis

21 January 2018

1 reference

A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day--a double-blind comparative trial

21 January 2018

1 reference

Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis

21 January 2018

1 reference

Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin

21 January 2018

1 reference

Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group

21 January 2018

1 reference

An evaluation of itraconazole in the management of onychomycosis

21 January 2018

1 reference

Treatment of onychomycosis with itraconazole

21 January 2018

1 reference

Efficacy and safety of itraconazole in the long-term treatment of onychomycosis

21 January 2018

1 reference

Onychomycosis Treated with Itraconazole or Griseofulvin Alone with and without a Topical Antimycotic or Keratolytic Agent

21 January 2018

1 reference

An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis

21 January 2018

1 reference

Single dose treatment of fungal nail disease

21 January 2018

1 reference

Effect of Terbinafine on the Pharmacokinetics of Cyclosporin in Humans

21 January 2018

1 reference

The effects of retinoids and terbinafine on the human hepatic microsomal metabolism of cyclosporin

21 January 2018

1 reference

Itraconazole interacts with felodipine

21 January 2018

1 reference

Interaction of itraconazole and digoxin

21 January 2018

1 reference

Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia

21 January 2018

1 reference

Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences

21 January 2018

1 reference

Possible interaction between phenobarbital, carbamazepine and itraconazole

21 January 2018

1 reference

Fluconazole and enhanced effect of rifabutin prophylaxis

21 January 2018

1 reference

Effect of fluconazole on the disposition of phenytoin

21 January 2018

1 reference

A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group

21 January 2018

1 reference

Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.17006

1 reference

8 October 2017

1 reference